Emily Howard

Emily’s PhD focused on human papillomavirus (HPV), which causes cervical cancer. She investigated how HPV evades innate immune detection. Her work crossed the fields of cancer biology, innate immunology and virology. She now provides patent advice in these areas as well as in the fields of vaccines, induced pluripotent stem cells, regenerative medicine, molecular biology, gene therapy and culturing cells.

Emily is experienced in drafting and has drafted multi-disciplinary cases, such as applications which relate to both promoter constructs and lipid assemblies, thereby crossing the fields of chemistry and biotechnology. 

Emily does a large amount of work for both Japanese and US companies, including large multinational companies. She also handles portfolios for smaller UK-based companies. Emily devotes significant amounts of time to the development of IP strategies for such companies. For example, she has helped devise strategies relating to the filing and prosecution of applications across multiple jurisdictions. Also, she has been heavily involved in developing strategies for analysis in freedom to operate matters. Emily is particularly experienced in relation to freedom to operate matters. She has worked closely with in-house counsel on both strategic and practical matters, such as determining the best use of resources. 

Emily has also been involved in successfully defending a number of European patents during opposition proceedings. 

Emily joined J A Kemp in 2011 and became an associate in 2018.